Anchor Therapeutics Obtains $10,000,000 New Financing

  • Feed Type
  • Date
    8/20/2010
  • Company Name
    Anchor Therapeutics
  • Mailing Address
    67 Rogers St. Cambridge, MA 02142
  • Company Description
    Anchor Therapeutics is developing first-in-class pepducin drug candidates, novel molecules that can selectively target G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling.
  • Website
    http://www.anchortx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    TVM Capital
  • Venture Investor
    HealthCare Ventures
  • Venture Investor
    Novartis BioVenture Fund

By posting a comment, you agree to our terms and conditions.